Literature DB >> 12704385

Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.

Mathias Oelke1, Marcela V Maus, Dominic Didiano, Carl H June, Andreas Mackensen, Jonathan P Schneck.   

Abstract

Adoptive immunotherapy holds promise as a treatment for cancer and infectious diseases, but its development has been impeded by the lack of reproducible methods for generating therapeutic numbers of antigen-specific CD8(+) cytotoxic T lymphocytes (CTLs). As a result, there are only limited reports of expansion of antigen-specific CTLs to the levels required for clinical therapy. To address this issue, artificial antigen-presenting cells (aAPCs) were made by coupling a soluble human leukocyte antigen-immunoglobulin fusion protein (HLA-Ig) and CD28-specific antibody to beads. HLA-Ig-based aAPCs were used to induce and expand CTLs specific for cytomegalovirus (CMV) or melanoma. aAPC-induced cultures showed robust antigen-specific CTL expansion over successive rounds of stimulation, resulting in the generation of clinically relevant antigen-specific CTLs that recognized endogenous antigen-major histocompatibility complex complexes presented on melanoma cells. These studies show the value of HLA-Ig-based aAPCs for reproducible expansion of disease-specific CTLs for clinical approaches to adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704385     DOI: 10.1038/nm869

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  110 in total

Review 1.  Reversing T cell immunosenescence: why, who, and how.

Authors:  Pierre Olivier Lang; Sheila Govind; Richard Aspinall
Journal:  Age (Dordr)       Date:  2012-02-26

Review 2.  Immunoinformatics: an integrated scenario.

Authors:  Namrata Tomar; Rajat K De
Journal:  Immunology       Date:  2010-08-16       Impact factor: 7.397

3.  Controlled major histocompatibility complex-T cell receptor signaling allows efficient generation of functional, antigen-specific CD8+ T cells from embryonic stem cells and thymic progenitors.

Authors:  Jian Lin; Hui Nie; Phillip W Tucker; Krishnendu Roy
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

Review 4.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

5.  HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays.

Authors:  Jennifer D Stone; Walter E Demkowicz; Lawrence J Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-23       Impact factor: 11.205

Review 6.  T lymphocytes targeting native receptors.

Authors:  Cliona M Rooney; Ann M Leen; Juan F Vera; Helen E Heslop
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells.

Authors:  Joel C Sunshine; Karlo Perica; Jonathan P Schneck; Jordan J Green
Journal:  Biomaterials       Date:  2013-10-05       Impact factor: 12.479

Review 8.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Authors:  Malarvizhi Durai; Christine Krueger; Zhaohui Ye; Linzhao Cheng; Andreas Mackensen; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Immunol Immunother       Date:  2008-06-18       Impact factor: 6.968

Review 10.  Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.

Authors:  Mathias Oelke; Jonathan P Schneck
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.